Expertise in
3
conditions

Carlos A. Roca-Gomez

Toulouse, FR 
Expertise in
3
conditions
Toulouse, FR 

Overview

Carlos Roca-Gomez practices practicing medicine in Toulouse, France.

Mr. Roca-Gomez is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Pigmented Villonodular Synovitis, Melanoma, Colorectal Cancer, NUT Carcinoma, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 95 peer reviewed articles and participating in 9 clinical trials.

Gender

Male

Locations

Toulouse, France
Other Locations
Villejuif, 94805, France
Paris, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors
Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: July 24, 2026
Intervention Type: Drug
Study Drugs: Association atezolizumab, BDB001
Study Phase: Phase 2
A European, Multi-centre Phase II Trial of Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck (HNSCC)
A European, Multi-centre Phase II Trial of Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck (HNSCC)
Enrollment Status: Completed
Publish Date: April 24, 2026
Intervention Type: Drug
Study Drugs: Atezolizumab, Bevacizumab
Study Phase: Phase 2
Efficacy of Regorafenib as Maintenance Therapy in Non-adipocytic Soft Tissue Sarcoma Having Received First-line Doxorubicin-based Chemotherapy
Efficacy of Regorafenib as Maintenance Therapy in Non-adipocytic Soft Tissue Sarcoma Having Received First-line Doxorubicin-based Chemotherapy
Enrollment Status: Completed
Publish Date: March 18, 2026
Intervention Type: Drug
Study Drug: Regorafenib
Study Phase: Phase 2
Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients
Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Drug, Radiation
Study Drugs: Olaparib, Temozolomide (TMZ)
Study Phase: Phase 1/Phase 2
A Phase 1, First-in-Human, Open-Label Study to Assess the Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours
A Phase 1, First-in-Human, Open-Label Study to Assess the Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours
Enrollment Status: Completed
Publish Date: September 02, 2025
Intervention Type: Drug
Study Drug: EVT801
Study Phase: Phase 1
A Phase 1 Study of LY3434172, a Bispecific Antibody Monotherapy in Advanced Solid Tumors
A Phase 1 Study of LY3434172, a Bispecific Antibody Monotherapy in Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: January 15, 2025
Intervention Type: Drug
Study Phase: Phase 1
Multiorgan Metabolic Imaging Response Assessment of Abemaciclib
Multiorgan Metabolic Imaging Response Assessment of Abemaciclib
Enrollment Status: Completed
Publish Date: March 15, 2024
Intervention Type: Drug
Study Drug: Abemaciclib
Study Phase: Phase 2
A Dose Escalation Phase I Study With an Extension Part Evaluating the Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With a Small Molecule CSF-1R Tyrosine Kinase Inhibitor (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers
A Dose Escalation Phase I Study With an Extension Part Evaluating the Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With a Small Molecule CSF-1R Tyrosine Kinase Inhibitor (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers
Enrollment Status: Completed
Publish Date: September 05, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Prospective,Multicenter, Phase II Study to Evaluate the Contribution of the Imaging TEP to the Expression of intégrines αvβ3 for the Characterization of the Residual Masses of Non-seminoma Tumors at the End of Chemotherapy
A Prospective,Multicenter, Phase II Study to Evaluate the Contribution of the Imaging TEP to the Expression of intégrines αvβ3 for the Characterization of the Residual Masses of Non-seminoma Tumors at the End of Chemotherapy
Enrollment Status: Completed
Publish Date: July 09, 2020
Intervention Type: Other
Study Phase: Phase 2
View 8 Less Clinical Trials

95 Total Publications

Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study.
Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study.
Journal: Journal for immunotherapy of cancer
Published: February 02, 2026

Frequently Asked Questions about Carlos A. Roca-Gomez

Is Carlos A. Roca-Gomez a top-rated expert for Pigmented Villonodular Synovitis?

MediFind is an objective health platform that identifies experts based on real-world data. Carlos A. Roca-Gomez is classified as an Advanced expert for Pigmented Villonodular Synovitis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Carlos A. Roca-Gomez participate in research or clinical trials?

Yes. Carlos A. Roca-Gomez has published 95 articles and abstracts on conditions like Pigmented Villonodular Synovitis. You can view a list of Carlos A. Roca-Gomez's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Roca-Gomez's expertise for a condition
ConditionClose
      View All 23 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile